A Follow-Up Study of Patients With HBeAg Positive Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML22265
NCT01645969 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65
Last updated 2016-11-02
Summary
This multicenter, prospective, observational study will evaluate the one-year outcomes in HBeAg positive chronic hepatitis B patients who had received Pegasys (peginterferon alfa-2a) in Arm A of study ML22265. Data will be collected from each patient for up to one year post-therapy.
Conditions
- Hepatitis B, Chronic
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Trials · Hoffmann-La Roche
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-04-30
- Primary Completion
- 2012-10-31
- Completion
- 2012-10-31
Countries
- China
Study Locations
More Related Trials
-
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B
NCT01734018 ·Status: COMPLETED
-
Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment
NCT00226382 ·Status: COMPLETED ·Phase: PHASE4
-
An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy
NCT02068365 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue
NCT01855997 ·Status: COMPLETED
-
A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
NCT02791269 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies
NCT00962975 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
NCT01220596 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.
NCT01519921 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys
NCT01011738 ·Status: COMPLETED
-
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B
NCT00922207 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).
NCT00435825 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study of Peginterferon Alfa-2a (PEGASYS®) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B
NCT01667432 ·Status: COMPLETED
-
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
NCT01519960 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)
NCT01641926 ·Status: TERMINATED ·Phase: PHASE3
-
A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B
NCT00927082 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B
NCT01143662 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression
NCT01706575 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B
NCT00940485 ·Status: COMPLETED ·Phase: PHASE4
-
Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B
NCT01311947 ·Status: COMPLETED
-
A Study of Switch From Nucleotide to Peginterferon Alfa-2a in CHB Patients Achieving HBeAg Loss and HBV DNA <200IU/ml
NCT01464281 ·Status: UNKNOWN ·Phase: NA
-
An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B
NCT01787279 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HbeAg-negative Chronic Hepatitis B (Perseas)
NCT01283074 ·Status: COMPLETED
-
A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253
NCT01697501 ·Status: COMPLETED ·Phase: PHASE3
-
Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults
NCT02822547 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.
NCT01179594 ·Status: WITHDRAWN ·Phase: PHASE4